


## Author Index

- Akaike, T., 271  
Akutsu, T., 225  
Alakhov, V., 111  
Allen, C., 3  
Altinok, H., 71  
Aoyagi, T., 193, 235  
Attwood, D., 71
- Batrakova, E., 111, 289  
Bazile, D., 171  
Bonadio, J., 279  
Booth, C., 71  
Bronich, T.K., 241  
Bronitch, T., 111  
Burt, H.M., 159
- Cammas-Marion, S., 205  
Carlisle, R.C., 259  
Clark Jr., C.G., 43
- Davis, S.S., 145
- Eisenberg, A., 3, 241  
Embree, L., 159
- Ferdous, A., 271  
Fisher, K.D., 251  
Fukushima, S., 225
- Garnett, M.C., 145  
Goldstein, S.A., 279  
Gorry, P.A., 71  
Govender, T., 145
- Han Bae, Y., 183  
Havredaki, V., 71  
Huang, H., 43  
Hunter, W.L., 159
- Illum, L., 145
- Jeong, B., 183
- Kabanov, A., 111, 289  
Kabanov, A.V., 1, 241, 319  
Kabanov, V.A., 27, 241  
Kataoka, K., 1, 133, 205, 225, 235  
Kato, M., 133  
Kelarakis, A., 71  
Klinski, E., 111  
Kohori, F., 193  
Kowalewski, T., 43  
Kwon, G.S., 215
- Labhasetwar, V., 279  
Levy, R.J., 279  
Li, S., 111  
Li, Y., 215
- Machida, M., 225  
Maruyama, A., 271  
Mashiba, H., 225  
Maysinger, D., 3  
Menger, F.M., 27  
Miller, D.W., 319
- Nagarajan, R., 53  
Nagasaki, Y., 133  
Nehls, A., 241  
Nixon, S.K., 71
- Ohnishi, Y.-i., 271  
Okamoto, K., 225  
Okano, T., 193, 205, 225, 235
- Pietrzynski, G., 111  
Plard, J.-P., 171
- Rakhnyanskaya, A.A., 27  
Rapoport, N., 91  
Read, M.L., 259  
Riley, T., 145
- Sakai, K., 193  
Sakurai, Y., 193, 225, 235  
Seymour, L.W., 251, 259  
Shimizu, K., 225  
Stolnik, S., 145  
Sugi, K.-i., 235
- Tanaka, S., 225  
Thurmond II, K.B., 43  
Toleikis, P., 159  
Torchilin, V.P., 303  
Torigoe, H., 271
- Venne, A., 111  
Vinogradov, S., 289
- Wan Kim, S., 183  
Ward, C.M., 251  
Watanabe, H., 271  
Wolfert, M.A., 259  
Wooley, K.L., 43
- Xiong, C.D., 145
- Yamamoto, Y., 133  
Yamato, M., 193  
Yaroslavov, A.A., 27  
Yaroslavova, E.G., 27  
Yokoyama, M., 193, 225
- Zhang, X., 159



## Subject Index

- Adriamycin, 193, 225  
Adriamycin dimer, 225  
Albumin, 251  
All-*trans*-retinoic acid, 241  
Anticancer drug, 225  
Antisense oligonucleotide, 289  
Associates, 235
- Biocompatibility, 159  
Biodegradable, 183  
Biodistribution, 159  
Block, 43  
Block copolymer, 183  
Block copolymer micelles, 3, 53  
Block copolymers, 111, 241  
Blood–brain barriers, 319  
Blood–cerebral spinal fluid barriers, 319
- Central nervous system, 319  
Coagulation, 171  
Colloidal stability, 145  
Conjugate, 215  
Conjugation of charged peptides, 133  
Copolymer, 43  
Copolymer micelles, 133  
Counterion condensation, 271  
Cross-linked, 43  
Cytotoxicity, 193
- Dextran, 271  
Diagnostic imaging, 303  
Diblock copolymer, 159, 215  
Diblock copolymers, 71  
DNA, 251, 259, 279  
Doxorubicin, 91, 111, 241  
Drug carriers, 205  
Drug delivery, 91  
Drug delivery systems, 279  
Drug targeting, 225  
Duplex DNA, 271
- Electron paramagnetic resonance, 91
- Fluorescence spectroscopy, 91
- Gelation, 71  
Gene therapy, 259, 279  
Graft copolymer, 271
- Hydrogel, 289  
Hydrogen bonding, 235  
Hydrophobic drugs, 3
- Integrin, 259  
Interpolyelectrolyte complex, 271  
Intravenous toxicity, 171
- Methotrexate, 215  
Micellar solubilization, 159  
Micelle, 183  
Micelles, 205, 303  
Micelle stabilization, 91  
Micellisation, 71  
Micellization, 91  
Morphology of micelles, 3  
Multidrug resistance, 289  
Multidrug resistant tumours, 111
- Nanoparticles, 145, 171, 289  
Nanospheres, 43
- Oleic acid, 241  
Oxyethylene/oxypropylene, 71
- Paclitaxel, 159, 241  
PEG-PLGA-PEG, 183  
PEO–PPO–PEO triblock copolymers, 53  
Peptide delivery, 235  
PLA–PEG, 145  
Pluronic, 91, 111  
Pluronic® block copolymers, 53  
Polycations, 27  
Poly(D,L-lactic acid), 171  
Poly(D,L-lactide), 193  
Poly(ethylene glycol), 289

- Polyethylene glycol, 171  
Poly(ethylene glycol)-poly(D,L-lactide), 133  
poly(ethylene glycol)-poly(L-aspartic acid) copolymer, 235  
Polyethyleneimine, Drug delivery, 289  
Poly(ethylene oxide), 215  
Poly(L-lysine), 251, 259, 271  
Polymer, 279  
Polymeric drug carrier, 235  
Polymeric drug delivery systems, 319  
Polymeric micelle, 225  
Polymeric micelles, 91, 193, 215, 303  
Polymers, 27  
Polymer-surfactant complexes, 241  
Poly(*N*-isopropylacrylamide), 193
- Rat, 171  
RGD, 259  
Ruboxyl, 91
- Safety, 171  
Shell, 43  
Site-specific, 205  
Solubilize-induced aggregate shape transitions, 53  
Solubilization in micelles, 53  
Solubilization of hydrocarbons, 53  
Spherical, cylindrical and lamellar aggregates, 53  
Sustained action, 279
- Thermal response, 193  
Thermodynamics of solubilization, 53  
Thermosensitive, 183  
Transfection, 259  
Triplex DNA, 271  
Turbidometry, 251
- Ultrasound, 91
- Vasopressin, 235  
Vesicles, 27

